WO2025195505 - MEMBRANE-ASSOCIATED TYROSINE AND THREONINE KINASE INHIBITOR COMPOUND AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/195505
Publication Date
25.09.2025
International Application No.
PCT/CN2025/084113
International Filing Date
21.03.2025
Title **
[English]
MEMBRANE-ASSOCIATED TYROSINE AND THREONINE KINASE INHIBITOR COMPOUND AND USE THEREOF
[French]
COMPOSÉ INHIBITEUR DES TYROSINE ET THRÉONINE KINASES ASSOCIÉES À LA MEMBRANE ET SON UTILISATION
[Chinese]
膜缔合酪氨酸和苏氨酸激酶抑制剂化合物及其应用
Applicants **
HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD.
Inventors
ZHU, Dongxing
WANG, Tao
ZHOU, Yike
ZHU, Wei
LI, Zhengtao
TANG, Renhong
Priority Data
202410336501.0
22.03.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1834 | |
| EPO | Filing, Examination, Granting | 12359 | |
| Japan | Filing, Examination, Granting | 2185 | |
| South Korea | Filing, Examination, Granting | 2199 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
23,317
Contact Us
Abstract[English]
The present disclosure relates to a PKMYT1 inhibitor compound represented by formula (II') or a stereoisomer or pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound or a stereoisomer or pharmaceutically acceptable salt thereof, and the use of same in the prevention or treatment of PKMYT1-related diseases.[French]
La présente invention concerne un composé inhibiteur de PKMYT1 représenté par la formule (II') ou un stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci, son procédé de préparation, une composition pharmaceutique contenant le composé ou un stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci, et son utilisation dans la prévention ou le traitement de maladies associées à PKMYT1.[Chinese]
本公开涉及式(II')所示PKMYT1抑制剂化合物或其立体异构体或其药学上可接受的盐、其制备方法、含有该化合物或其立体异构体或其药学上可接受的盐的药物组合物、以及其在预防或治疗PKMYT1相关疾病中的用途。